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ABSTRACT
Delivery of DNA to cells and its subsequent integra-
tion into the host genome is a fundamental task in
molecular biology, biotechnology and gene therapy.
Here we describe an IP-free one-step method that en-
ables stable genome integration into either prokary-
otic or eukaryotic cells. A synthetic mariner transpo-
son is generated by flanking a DNA sequence with
short inverted repeats. When purified recombinant
Mos1 or Mboumar-9 transposase is co-transfected
with transposon-containing plasmid DNA, it pene-
trates prokaryotic or eukaryotic cells and integrates
the target DNA into the genome. In vivo integra-
tions by purified transposase can be achieved by
electroporation, chemical transfection or Lipofec-
tion of the transposase:DNA mixture, in contrast to
other published transposon-based protocols which
require electroporation or microinjection. As in other
transposome systems, no helper plasmids are re-
quired since transposases are not expressed inside
the host cells, thus leading to generation of stable
cell lines. Since it does not require electroporation
or microinjection, this tool has the potential to be
applied for automated high-throughput creation of li-
braries of random integrants for purposes including
gene knock-out libraries, screening for optimal inte-
gration positions or safe genome locations in differ-
ent organisms, selection of the highest production
of valuable compounds for biotechnology, and se-
quencing.
INTRODUCTION
Targeted genome modifications can be efficiently achieved
using the bacterial immunity-derived systemCRISPR-Cas9
(1–4). However, in some circumstances alternative methods
such as DNA transposition can provide a more appropriate
editing tool. For example, if the optimal position for a de-
sired genome integration is not known in advance and has
to be determined; or if random integrations are preferred
(5), for example to create libraries of clones (6,7); or to se-
quence new organisms by introducing a known marker in
uncharacterized genomes.
DNA transposase enzymes can recognize short, inverted
repeat (IR) DNA sequences, excise DNA flanked with IRs
(transposon) and integrate it into a new location (8). Trans-
posons have been successfully used to modify genomes of
prokaryotic and eukaryotic cells (9,10), and are being used
in preliminary clinical trials (11).
Currently DNA transposition––excision followed by in-
tegration of a gene––can be achieved by injection or co-
transfection of a donor plasmid, bearing a gene of inter-
est flanked by IRs, together with a helper plasmid express-
ing transposase (12–15). Active transposase, expressed in-
side the cell recognizes the transposon IRs on the donor
plasmid, excises the gene of interest and inserts it into ge-
nomic DNA. However, constant expression of the trans-
posase can result in excision of the newly integrated trans-
posons (16), or lead to overproduction inhibition, a feature
ofmariner family transposition (17–20). The in vivo activity
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of the mariner transposase Mos1 expressed from a helper
plasmid is much lower than that of piggyBac and Sleeping
Beauty transposases, themost promising representatives for
use in mammalian transgenesis (21). This may be because
Mos1 transposase is expressed in high quantities in vivo and
forms aggregates in cells, reducing the transposition effi-
ciency (20,22).
To solve the problem of constant expression of trans-
posase inside the cell, a single plasmid, carrying both the
transposon and the transposase expression genes, can be
transfected (23,24). Similar to the helper plasmid method,
the potential for recombination of the transposase gene
with the host genomic DNA makes this approach unsuit-
able for gene therapy. Moreover, the transposition rate is
dependent upon the intracellular protein expression level,
which limits the approach to strains and cell lines that en-
able sufficient expression levels.
In alternative approaches, purified protein or mRNA of
the transposase can be injected into a living cell to pro-
mote integration or excision of transposons in vivo (25–27).
The injection procedure is an invasive technique, which re-
sults in low throughput. Transfection of mRNA in mam-
malian cells was shown to be less efficient than the use of
the helper plasmid, possibly due to the short window of
expression before the mRNA is degraded (28–30). piggy-
Bac transposase was successfully packaged and delivered to
mammalian cells by lentiviral particles, but this delivery ap-
proach was not feasible with other transposases (31).
Several commercially available kits use Tn5, Mu or Tn7
transposons for insertionalmutagenesis (Epicentre®, Ther-
moFisher Scientific Inc., New England Biolabs® Inc.). Tn5
and Mu were shown to be active for in vivo integration,
for example, in the widely used EZ-Tn5™system, but pub-
lished protocols require electroporation (32) or microinjec-
tion (33,34) and are thus unsuitable for automated high-
throughput approaches.
In order to overcome these limitations we have developed
a method in which purified recombinant mariner trans-
posases,Mos1 andMboumar-9, deliver and integrate DNA
of interest in vivo into genomes of bacterial and mam-
malian cells following facile transfection: chemical transfec-
tion, electroporation or Lipofection. This will broaden the
spectrum of organisms suitable for in vivo mutagenesis, de
novo sequencing, genome-wide functional screening, since
it allows a simple and automatable transfection method to
be used to deliver and integrate DNA of interest into the
genome.
MATERIALS AND METHODS
In vivo transposition assay and inhibition
Plasmid DNA (7 nM) carrying the gene of inter-
est and flanked with short IRs (5′-tatcaggtgtaca
agtatgaaatgtcgttt-3′ for Mos1 transposition or 5′-
taccaggtgtgtcggtaattcctttccggttttt-3′ for Mboumar-9
transposition) was incubated with 70 nM purified
transposase (protein:DNA molar ratio 10:1) for 1 h at
30◦C in buffer containing 25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 7.5, 100 mM
NaCl, 10% v/v glycerol, 2 mM dithiothreitol (DTT), 200
g/ml acetylated bovine serum albumin, 10 mM MnCl2
in final volume 20 l. The inhibition of the pre-incubation
step was performed by addition of proteinase K to a
final concentration of 1 mg/ml prior to additional 30 min
incubation at 37◦C (for Figure 2C). In vivo transposition
also occurs if the pre-incubation step is omitted, but with
∼10× less efficiency.
For bacterial and mammalian cells chemical transfec-
tions the whole reaction volume (20 l) was used, whereas
for electroporation 2 l of the reaction was used.
Preparation of chemically competent cells
A single colony was used to inoculate 5 ml Lysogeny Broth
(LB) from a freshly streaked plate, and incubated overnight
at 37◦C with 250 rpm agitation. The culture was diluted
1:200 into 100 ml pre-warmed LB with 20 mM MgCl2
and incubated at 37◦C with 250 rpm agitation until OD600
reached 0.48 for Escherichia coli DH10B. The culture was
transferred to a chilled 250 ml centrifuge bottle and incu-
bated on ice for 10 min. The cells were harvested for 5 min
at 4000 g at 4◦C. The pellet was resuspended in 40ml of cold
TFB1 buffer (30 mM CH3COOK, 100 mM RbCl, 10 mM
CaCl2, 50 mMMnCl2, 15% v/v glycerol, pH 5.8) by gently
pipetting and incubated on ice for 5 min. Cells were then
pelleted for 10 min at 1400 g at 4◦C. The pellet was gently
resuspended in 4 ml of cold TFB2 buffer (10 mM MOPS,
75 mMCaCl2, 10 mMRbCl, 15% v/v glycerol, pH 6.5) per
100 ml of culture and incubated on ice for 15 min. Aliquots
of 100 l were dispensed into pre-chilled 1.5 ml microcen-
trifuge tubes. Tubes were stored at −80◦C after snap freez-
ing in liquid nitrogen.
Bacterial transfection
Chemically competent E. coli DH10B were prepared using
the RbCl method, as described above. The transposition re-
action (20 l) was added to the cells thawed on ice, tubes
were gently flicked and incubated on ice for 30min. After 90
s heat shock in a 42◦C water bath, the tubes were returned
to ice for 2 min and 400 l of SOC medium (room tem-
perature) was added. The tubes were incubated for 80 min
at 37◦C and 200 rpm shaking prior to plating on LB agar
containing kanamycin 50 g/ml. The colonies were scored
after 20 h incubation at 37◦C.
Commercially available competent cells: one Shot®
TOP10 Chemically Competent E. coli (Invitrogen) (for Fig-
ure 3C) and One Shot® TOP10 Electrocomp™ E. coli (for
Figure 3A)––were used according to the manufacturers’ in-
structions.
Protein cloning and purification
Mos1 and Mboumar-9 transposases were purified as previ-
ously described (35,36).
The N-terminal Green Fluorescent Protein (GFP) fu-
sion of Mos1 was assembled with pET30a expression vec-
tor (Novagen) using the PaperClip DNA assembly method
(37). A flexible linker (GGGGS)3 was inserted between the
GFP and Mos1 sequences according to the published pro-
tocol for intervening sequences (37).
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Sequence verified plasmids were transformed into E. coli
BL12 Gold (DE3). Protein expression was induced in Ter-
rific Broth with IPTG at a final concentration of 1 mM at
OD600 = 0.6 for 21 h at 220 rpm agitation and 25◦C. Cells
were collected at 8000 g for 1 h at +4◦C. Five grams of
cell pellet was resuspended in 50 ml buffer containing 20
mM NaPO4 pH 7.4, 500 mM NaCl, 5 mM MgCl2, 1 Ku-
nitz DNase, 400 g/ml lysozyme, 2 tablets Complete Pro-
tease inhibitor cocktail (Roche) and incubated for 1 h at
+4◦C with agitation. The cell suspension was homogenized
by passing through a needle and cells were broken down in
a Cell Disruptor (1.1 kW TS) at 25 kpsi. Cell debris was
pelleted at 50 000 g for 1 h at 4◦C. Supernatant was filtered
through a 5 m filter followed by a 0.45 m filter (Milli-
pore) and imidazole was added to a final concentration of
2 mM, prior to loading onto a HiTrap IMAC FF 1 ml col-
umn charged with Ni2+. The column was pre-equilibrated
with 20 mM NaPO4 pH 7.0, 300 mM NaCl, 10 mM Imi-
dazole. The injection flow rate was 1 ml/min. The column
was washed with two column volumes (CV) of equilibration
buffer and bound proteins were eluted with a linear gradi-
ent from 20 mM NaPO4 pH 7.0, 300 mM NaCl, 10 mM
Imidazole to 20 mM NaPO4 pH 7.0, 300 mM NaCl, 500
mM Imidazole over 10 CV. Fractions (1 ml) were collected
and analyzed by sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) using 12% polyacrylamide
gels. Fractions containing bands of the expected size were
pooled and concentrated to 250 l using a Vivaspin® 6
mwco 10 000Da. Further purification and analysis was per-
formed on a Superdex 200 10/300GL column at 0.5ml/min
flow rate. The final protein purity was estimated by Image-
Lab Software to be 75–80%.
Southern blotting
Genomic DNA (1 g) was separated on a 1% (w/v) agarose
gel after overnight endonuclease digestion with EcoRI New
England Biolabs (NEB). The gel was washed twice with
dH2O, incubated with the depurination solution (0.2 M
HCl) for 20 min with gentle shaking and rinsed with dH2O.
The DNA was denaturated by 2 × 15 min incubation with
0.5 M NaOH, 1.5 M NaCl with gentle shaking and rinsed
with dH2O. The solution was neutralized by 30 min incuba-
tion in 0.5 M Tris pH 7.5, 1.5 M NaCl with gentle shaking,
rinsed with dH2O and finally equilibrated for 30 min in 20×
Saline Sodium Citrate (SSC) solution (3 M NaCl, 30 mM
sodium citrate) with gentle shaking.
Capillary transfer was performed overnight at room tem-
perature: the membrane was then rinsed with dH2O and
cross-linked for 90 s under UV (UV Stratalinker 1800).
Pre-hybridization was performed in a plastic bag at 55◦C
for 1.5 h in 8 ml of hybridization solution with 120 rpm
agitation. Hybridization was performed at 55◦C for 15 h
in a plastic bag containing 5 ml of hybridization solution
with 3 l of 100 M fluorescently labeled 28 bp Mos1 IR
(5′ IRDye® 700, IDT) with 120 rpm agitation. The mem-
brane was washed for 5 min at room temperature in 2×
Saline-Sodium Phosphate-Ethylenediaminetetraacetic acid
(SSPE) , 5 min at 40◦Cmin 2× SSPE, 2× for 15 min at 50◦C
in 2× SSPE/1% SDS, 2× for 15 min at 50◦C in 0.2× SSPE.
Fluorescent dye was visualized on a LI-COR Imaging Sys-
tem using Odyssey software.
Sequencing of prokaryotic genome integration sites
Integrations in the bacterial genome were mapped by two
methods: cloning of genomic DNA and inverse polymerase
chain reaction (PCR).
For cloning of genomic DNA 5 g of genomic DNA and
1g of pBSKS(+) was digested with EcoRI (NEB) in a final
volume 50 l overnight at 37◦C. The enzyme was heat inac-
tivated and 100 ng of pBSKS(+) was ligated with 400 ng of
genomic DNA with T4 DNA ligase (NEB) in final volume
10l at 4◦Covernight. The whole reaction was transformed
intoE. coliDH10B chemically competent cells. After recov-
ery the total volume was plated out on LB agar containing
kanamycin (50 g/ml) and carbenicillin (100 g/ml). Plas-
mid DNA was isolated from the resistant clones and ana-
lyzed by restriction digest and Sanger sequencing.
Inverse PCR: ∼1 g of genomic DNA was digested with
1 l of EcoRI (NEB) in 20 l for 3 h at 37◦C. The endonu-
clease was heat inactivated for 20 min at 65◦C. Two dilu-
tions (1:10 and 1:20) were prepared for self-ligation of the
genomic DNA fragments in a final volume of 20 l at room
temperature with Rapid DNA Ligation Kit (Roche) for 20
min.
PCR was performed with Phusion High-Fidelity Poly-
merase (ThermoScientific) in a final volume of 20 l, us-
ing 400 M dNTPs (Invitrogen), 500 nM of primers (5′-
gtttcccgttgaatatggctc-3′ and 5′-actttctggctggatgatgg-3′), 1
l of DNA ligation mixture, 3% v/v Dimethyl sulfoxide
(DMSO), 0.2l of Phusion Polymerase, dH2O to 20l. The
initial denaturation step was 98◦C for 30 s, followed by 30
cycles of 98◦C for 30 s, 56◦C for 20 s and final elongation of
72◦C for 7 min. The whole PCR reaction was analyzed on a
1% (w/v) agarose gel. The brightest bands were cut out, gel
purified (Qiagen) and sequenced.
Construction of transposons
The transposon containing the kanamycin resistance cas-
sette only was constructed previously (38). We used donor
plasmids with either two right Mos1 IRs (pEPMosRR) or
with two left Mboumar-9 IRs (pEPMboLL) as they were
shown to be the most efficient for in vitro transposition (38).
The SalI site within the backbone pEP185.2 was deleted by
site directed mutagenesis using primers 5′-ccctcgaggtagacg
gtatcgataagc-3′ and 5′-gcttatcgataccgtctacctcgaggg-3′. The
kanamycin cassette was cut out of the plasmid using the re-
maining two SalI sites, leaving the IRs within the backbone
vector. The new inserts were amplified using primers 5′-a
tttatgtcgaccgctgaggtctgcctcg-3′ and 5′-ttaaatgtcgacggatcca
ggctcatccagcc-3′ or 5′-ttaaatgtcgactctagattcggagtgagc-3′ an
d 5′-taagatgtcgacttcaaatatgtatccgctcatg-3′ from the plas-
mid products of three-, four-, five- and six-parts assemblies
by PaperClip (37). The larger transposons were obtained
in this study by assembly of seven, eight and nine parts
in pSB1C3 according to the PaperClip protocol including
boost PCR (Supplementary Table S3). These transposons
were also amplified with the primers 5′-ttaaatgtcgactctag
attcggagtgagc-3′ and 5′-taagatgtcgacttcaaatatgtatccgctcat
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g-3′, which introduced flanking SalI sites and were cloned
into pre-digested and gel-purified backbone pEP185.2 car-
rying the IR sequences.
To create the donor plasmid for mammalian cell trans-
fection, the neomycin gene (neoR) under the regulation of
the SV40 promoter was used. We deleted the SalI site from
pBSKS(+) with site directedmutagenesis using primers 5′-g
cttatcgataccgacgacctcgaggggg-3′ and 5′-ccccctcgaggtcgtcg
gtatcgataagc-3′ creating pBSKS(+)SalI. Then we sub-
cloned the kanR gene with the IRs sequences from pEP-
MosRR (digested with XbaI) and from pEPMboLL (di-
gested with SacI) into pBSKS(+)SalI using the appropri-
ate sites. The kanamycin resistance cassette was cut out of
both transposons with SalI. The neomycin resistance cas-
sette of 1.6 kb was amplified from the pEGFP-C1 vector
with the primers 5′-tccatagtcgacagtcctgaggcggaaagaacc-3′
and 5′-tccatagtcgacatgagtaacctgaggctatggc-3′ introducing
SalI recognition sites. The resulting products were cloned
using the SalI sites into the prepared vectors with two right
IRs of Mos1 or two left IRs of Mboumar-9 transposons,
creating pMosNeo and pMboNeo plasmids. The correct or-
der and absence of mutations of the resulting constructs
were confirmed by sequencing.
Tissue culture
HeLa cell line (ATCC® CCL-2) was maintained in
DMEM (Dulbecco’s Modified Eagle Medium) (Gibco®,
No. 41966), containing 10% fetal bovine serum (SIGMA,
F7524) and 1% penicillin-streptomycin (SIGMA, P4333).
HEK293-H cell line (Gibco®, No. 11631-017) was main-
tained inDMEM (Gibco®, No. 41966), containing 10% fe-
tal bovine serum (SIGMA, F7524) and supplemented with
0.1 mMMinimumEssentialMedium (MEM) non-essential
amino acids (Gibco®, No. 11140).
Cells were inoculated into 6-well plates, one day before
transfection in several dilutions (0.8–3.2 × 105 cells per
well). For transfection, cells of 60–70% confluence were
used. The growth medium was aspirated, and cells were
washed with 2 ml of Dulbecco’s Phosphate-Buffered Saline
(DPBS) (Gibco®, No. 14190094), then with 2 ml of Opti-
MEM® Reduced Serum (Gibco®, No. 31985).
For each transfection reaction, 1 tube containing 245 l
ofOpti-MEM® with 3–5l of either Lipofectamine® 2000
orGeneJuice® and 1 tube with 230l of Opti-MEM® plus
the whole volume (20 l) of the transposition reaction were
prepared, and incubated at room temperature for 5 min. (If
the volume of the transposition reaction was <20 l, the
volume of Opti-MEM® was increased tomaintain the final
volume of 250l). The solution containingDNAwas added
drop-wise to the tubes containing transfection reagent (with
no vortexing or mixing). The tubes were incubated at room
temperature for 30 min and each 500 l was added drop-
wise to 1.5 ml of DMEM in each well. The plate was rocked
gently and incubated for 24 h prior to medium changing
and/or splitting the cells for selection. For selection G418
was added to a final concentration of 1200 g/ml for HeLa
cells or 1000 g/ml for HEK293-H cells after 72 h after
splitting the cells.
Selection was performed for 10–14 days (until visible
colonies were formed). Colonies were fixed in ice-cold
Figure 1. In vitro transposition assay (in vitro hop assay). A donor plasmid
contains a selection cassette (kanamycin resistance,KanR) flankedwith the
inverted repeats (IR), which are recognized by transposase. Upon addition
of divalent ions Mg2+ or Mn2+in vitro, purified transposase excises the se-
lection cassette and integrates it into the target plasmid. Purified products
of in vitro transposition can be analyzed by transfection into Escherichia
coli DH10B cells and selection in the presence of kanamycin. The donor
plasmid contains a conditional origin of replication oriR6K and will not
propagate in the destination strain; only the kanamycin cassette containing
target plasmids are maintained.
methanol for 5–10 min, stained with 0.1% (w/v) brilliant
blue in methanol for 15 min and washed with DPBS until a
clear backgroundwas achieved. For cell counting, cells were
dissociated for 5min with 0.2 ml TrypLEExpress (Gibco®,
No. 12605-010) and the reaction was quenched with 0.5 ml
DPBS. Cells were countedwith aCountess™ Automated cell
counter (Invitrogen) according to themanufacturer’s proto-
col.
Sequencing of eukaryotic genome integration sites
HeLa cells from one well of a 6-well plate were trypsinized
and pelleted at 400 g for 5 min at room temperature. Ge-
nomic DNA was isolated with a Wizard® Genomic DNA
purification Kit (Promega). After overnight digestion of 2.5
g of genomic DNA with HindIII-HF, the restriction en-
zyme was heat inactivated for 20 min at 80◦C. DNA was
phenol extracted, ethanol precipitated and dissolved in 20
l of water, pre-warmed to 70◦C. Self-ligation was per-
formed overnight in 100 l total volume using 150 ng of
digested genomicDNAandT4DNALigase (NEB) accord-
ing to the manufacturer’s protocol. Ligated DNA was phe-
nol extracted, ethanol precipitated and dissolved in 20 l of
water pre-warmed to 70◦C.
To amplify both junctions flanking the neomycin re-
sistance cassette, inverse PCR was performed using PCR
Master Mix (Promega) with the addition of Pfu DNA
Polymerase (Agilent Technologies) in a final volume of
50 l: 25 l of Master Mix, 160 M dNTPs, 500
nM of primers (5′-gaggctaactgaaacacggaaggag-3′ and 5′-
cgggactatggttgctgactaattg-3′), 10 l of ligated DNA and
dH2O to 50 l. The initial denaturation step was 95◦C
for 2 min, followed by 40 cycles of 95◦C for 30 s, 63◦C
for 30 s, 73◦C for 3 min and final elongation of 73◦C for
5 min. Fifteen microliters of the PCR reaction was ana-
lyzed on a 1% (w/v) agarose gel. The brightest bands were
cut out, gel purified (Qiagen) and cloned into pJET plas-
mid using the CloneJET PCR Cloning Kit (ThermoFisher
Scientific) according to the manufacturer’s protocol. Car-
benicillin resistant colonies were selected overnight. Plas-
mid DNA was isolated and sequenced to establish the loca-
tions of neomycin cassette integrations in mammalian cells.
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Live cell imaging
Prior to transfection, cells were inoculated into a MatTek
glass bottomed dish (P35GC-1.5-14-C). Following transfec-
tion as described above, imagingwas performed at 37◦Cand
5% CO2 on a Deltavision Elite microscope with Photomet-
rics Coolsnap CCD camera and objective ×60 PlanApoN
NA 1.42 Oil. Images of the cells were taken every 20 min
during 61 time points and throughout 10 positions on a
dish. Data were analyzed using ImageJ v10.2. Twelve Z-
stacks (1 m), summed and the pixel intensity of a 5 m
circle of the cytoplasm and a 5m circle of the nucleus were
compared (excluding the points of saturation for the cam-
era). The averages of 10 positions on a dish are presented
and standard deviations are shown as shadowed error bars.
Western blotting
Total protein samples were isolated from cells by sonica-
tion in buffer D (20 mM Tris pH 7.9, 20% w/v glycerol,
0.1 M KCl, 0.2 mM Ethylenediaminetetraaceticacid, 0.5
mM DTT, 0.2 mM phenylmethylsulphonyl using Biorup-
tor Pico (Diagenode) and centrifugation at 5000 g for 10
min in 4◦C. Subsequently, 250 g of total protein ex-
tracts or recombinant purified proteins (GFP: 1 ng per
lane, GFP-Mos1: 10 ng per lane) were separated on 4–
12%NuPAGESDS-PAGEgels usingMOPS running buffer
(ThermoFisher) and were transferred onto a nitrocellulose
membrane (GE Healthcare). The membrane was blocked
overnight at 4◦C with 1:10 Western Blocking Reagent
(Roche) in Tris-buffered saline, Tween 20 (TBST) buffer (20
mM Tris pH 7.5, 137 mM NaCl and 0.1% (v/v) Tween
20). The next day, the membrane was incubated for 1 h
at RT with primary rabbit polyclonal anti-GFP (1:1000,
50430-2-AP, Proteintech) solution in 1:20 Western Block-
ing Reagent diluted in TBST. After washing in TBST, the
blots were incubated with the secondary anti-rabbit anti-
body (1:1000, #7074, Cell Signalling Technology) conju-
gated to horseradish peroxidase and were detected with
WesternSure PREMIUM Chemiluminescent Substrate de-
tection reagent using C-DiGit Blot Scanner (LI-COR).
RESULTS
In vivo integration in bacterial genomes
DNA transposition can be assayed by an in vitro hop assay,
in which a kanamycin resistance cassette, flanked by IRs,
moves from a donor to a recipient plasmid upon addition
of transposase and divalent cations (39) (Figure 1). After
transformation of the reaction product into E. coliDH10B,
the donor plasmid cannot replicate since it contains the con-
ditional origin of replication oriR6K, whereas kanamycin
resistant products of transposition (genomic integrations)
are selected and propagated. During optimization of this
protocol for Mos1 we noticed that if transposase protein
was not inactivated prior to transfection, kanamycin resis-
tant colonies were obtained (Figure 2A and B). The num-
ber of such colonies was reduced 10-fold after incubation of
the reaction products with proteinase K, and was reduced
to zero by phenol extraction of the reaction mixture (Fig-
ure 2C). Even though, in some colonies a low concentration
of the replication-deficient plasmid was detected by PCR
(Figure 2D, clone 1), these clones were unable to grow in
the presence of chloramphenicol––the resistance encoded
by the donor plasmid backbone (Figure 2E). We hypothe-
sised that the kanamycin resistant colonies could have been
products of genomic integration.
We suspected that the kanamycin-resistant clones re-
sulted from transposase:DNA complexes entering the
cells during transfection, followed by integration of the
kanamycin cassette into the E. coli genome. To investi-
gate this, we digested the genomic DNA of the kanamycin-
resistant clones and performed Southern Blot analysis by
hybridization with fluorescently labeled IR DNA (28 bp).
All the clones analyzed contained between one and three
integrations (Figure 2F). To confirm the in vivo integra-
tions, we sequenced the integration sites in genomic DNA
after Mos1 and Mboumar-9 transposition (Supplementary
Figure S1 and 2; Supplementary Table S1 and 2). Align-
ment of these sites for Mos1 transposition (Figure 2G) and
for Mboumar-9 transposition (Supplementary Figure S3)
showed that the integrations occurred with duplication of
the TA target site, confirming that they were indeed prod-
ucts of mariner transposition (40).
In our experiments, both electroporation and chemi-
cal transfection of purified mariner transposases resulted
in similar transposition efficiency in bacterial cells (Fig-
ure 3A). This observation indicates that the transfection
method in not a limiting step for transposition in vivo.
Size limitations for in vivo transposition
The efficiency of in vitro mariner transposition is dependent
upon the separation of the IRs (19,41): previously it was
observed that increasing the size of the transposon gene
causes dramatic reduction in Mos1 transposition efficiency
(42,43). To check the size limitation of the transposon gene
for in vivo transposition, we created eight different trans-
posons, ranging in size from 1.3–6.5 kb (Figure 3B and Sup-
plementary Table S3). To confirm that the full transposon
was integrated into the genome, we performed colony PCR
with primers complementary to the ends of each transpo-
son (Supplementary Figure S4). Interestingly, when com-
paring reactions that used equimolar amounts of the dif-
ferent donor plasmids, transposition efficiency decreased
only 3-fold between the longest and the shortest constructs
(Figure 3C). Sinzelle et al. observed 20-fold decrease in ef-
ficiency of transposition for Mos1 transposons of similar
sizes (43). Thus, we conclude that, at least within this range,
the size of the gene of interest is not a limiting factor for in
vivo transposition.
In vivo integration in mammalian genomes
Next we asked if in vivo transposition could be observed in
mammalian cell lines. TheG418 resistance gene was flanked
with IRs ofMos1 to create a donor plasmid (Figure 4A).We
found that after transfection of HeLa or HEK293-H cells
with donor plasmid together with purified transposase, we
obtained an increased number of G418 resistant colonies,
compared to the no-transposase control (Figure 4B, Sup-
plementary Figure S5). In the HeLa cell line after addition
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Figure 2. In vivo transposition in prokaryotic cells. (A) Scheme of the experimental method. The donor plasmid DNA, carrying a gene of interest
(kanamycin resistance cassette, KanR) flanked with (IRs), contains a conditional origin of replication, oriR6K, which prevents replication in the recipient
strain. Donor plasmid DNA and purified recombinant transposase (Mos1 orMboumar-9) are co-transfected into bacterial cells, resulting in integration of
the kanamycin cassette into the genomicDNA. (B) Kanamycin resistant colonies were obtained only if purified transposase was included in the transfection
reaction. White colonies on dark background. (C) Relative efficiency of transposition observed after treatment of the reactions, prior to transfection, with
proteinase K, phenol, no treatment and the control (no transposase added). Two technical repeats were performed for two biological repeats. (D) Agarose
gel of the products of colony polymerase chain reaction (PCR) to detect the presence of the donor plasmid in the kanamycin resistant colonies. Clone
1 (Lane 4) has traces of the donor plasmid backbone detected. Positive control––a colony of Escherichia coli S17  pir carrying donor plasmid; negative
control––a colony of the recipient strainE. coliDH10B. (E) Five analyzed clones are resistant to kanamycin, but sensitive to chloramphenicol––the plasmid
backbone resistance. Controls as in (D). (F) Southern Blotting analysis of the digested genomic DNA from the kanamycin resistant clones hybridized with
fluorescently labeled IR DNA. Negative control: genomic DNA of the recipient strain E. coli DH10B. (G) WebLogo alignment of 40 bp around the TA
target nucleotides duplication of the 14 integration sites by Mos1 in the bacterial genome.
of purified transposase, the number of G418 resistant cells
increased on average by a factor of 5 (Figure 4B, no dilu-
tion, 4C). The number of G418 resistant colonies increased
from 2 ± 0.7 (no transposase added) to 11 ± 4 (transposase
added) (Figure 4B, 1/12 dilution). Three integration sites
in the HeLa genome were sequenced directly: duplication
of the TA target dinucleotides confirmed that the insertions
were products of a mariner transposition reaction (Figure
4D). In the HEK293-H cell line the number of G418 resis-
tant colonies increased two times from 36 ± 7 (no trans-
posase added) to 67 ± 10 (transposase added) (Supplemen-
tary Figure S5, 1/6 dilution). The difference between HeLa
and HEK293-H cell lines response to in vivo transposition
might be due to several factors including but not limited to
higher transfection or higher recombination efficiencies of
the HEK293-H cell line.
In order to determine whether the transposase can in-
deed penetrate themammalian cellmembrane, we expressed
and purified an N-terminal GFP-Mos1 transposase fusion
with a flexible linker (GGGGS)3 (Figure 5A and B). Intro-
duction of the GFP cassette did not reduce the efficiency
of prokaryotic transposition in vivo when compared to un-
fused Mos1 transposase (Supplementary Figure S6).
During imaging of live cells, the transposase was visible
in the cell cytoplasm 80 min after transfection (Figure 5C).
After 3 h, the transposase protein formed aggregates in the
cytoplasm, and after 8 h, it penetrated the nuclear envelope.
By 20 h post-transfection, the highest transposase concen-
tration was in the nucleus, where in vivo transposition can
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Figure 3. Comparison of transfection methods and transposon sizes for in
vivo transposition. (A) In vivo transposition efficiency after electroporation
or chemical transfection. In vivo transposition efficiency is the number of
resistant colonies per microgram of the donor plasmid divided by the effi-
ciency of transfection of a standard plasmid (CFU/g). (B) Agarose gel of
the restriction analysis to confirm the correct size of each plasmid donor of
transposon assembled by PaperClip. (C) Correlation of the transposition
efficiency with the transposon size after Mos1 transposition. For panels A
and C two technical repeats were performed for two biological repeats.
occur (Figure 5D). To confirm that the GFP signal in the
nucleus is not due to diffusion of the GFP on its own, in
the event of GFP-Mos1 degradation inside the cells, we per-
formed a western blotting analysis of the HeLa cell extracts,
prepared at the same time points (Figure 5E). Our results
indicate that there is no detectable GFP-Mos1 degradation
20 h post-transfection. This is a direct confirmation that re-
combinant Mos1 transposase, expressed and purified from
Figure 4. In vivo transposition in eukaryotic cells. (A) Scheme of the ex-
perimental method. The donor plasmid DNA, carrying a gene of interest
(G418 resistance cassette) flanked with Mos1 IRs. Donor DNA and puri-
fied recombinant transposase are co-transfected into mammalian cells, re-
sulting in integration of the gene of interest into genomic DNA. (B) HeLa
cells after 11 days of selection (40× magnification), after 13 days of selec-
tion (no dilution) and after 10 days of selection (1/12 dilution). Addition of
the Mos1 transposase increases the number of G418-resistant cells. Three
biological repeats. (C) Quantification of the number ofG418 resistant cells.
Data are represented as average of six repeats (two technical repeats for
three biological repeats) ± standard deviation. *** P-value < 0.001. (D)
Localization of the integrations in mammalian genome. TA dinucleotides
were duplicated upon transposon DNA integration.
E. coli, can indeed penetrate mammalian cells during trans-
fection and concentrate in the nucleus retaining its integrity.
DISCUSSION
Taken together, our results show that two transposases of
the mariner family are able to facilitate integration of tar-
get DNA into the genome of living prokaryotic or eukary-
otic cells in vivo, without expression of the transposases in-
side the host cells. Transposase together with transposon
DNA were successfully introduced into bacterial or mam-
malian cells by electroporation or transfection. It has been
shown that co-transfection of restriction enzymes increases
the recombination rate in eukaryotic cells (44,45), but to
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Figure 5. Construction and imaging of GFP-Mos1 fusion transposase. (A) Mos1 and GFP-Mos1 transposase fusion protein constructs in pET30a expres-
sion vector. (B) Coomassie stained 12% SDS-PAGE in Tris-Glycine-SDS buffer of purified Mos1 and GFP-Mos1 transposases. (C) Live cell imaging with
60× magnification after transfection of HeLa cells with purified GFP-Mos1 transposase in complex with donor DNA. Scale bar is 10 m. Images are
representatives of 10 image points on a dish. (D) Quantification of the GFP signal in the nucleus and cytoplasm over time after transfection; 10 cells were
analyzed. Shadowed error bars represent the standard deviation. (E) Western blotting analysis of HeLa cells lysates after transfection with GFP-Mos1
and donor plasmid. Proteins were separated on 4–12% NuPAGE SDS-PAGE in MOPS buffer (buffer composition, acrylamide percentage and protein
concentration affect protein migration). Lane 1–1 ng of purified GFP, lane 2–10 ng of purified GFP-Mos1, lane 3-mock, no transposase or DNA was
added to the cells. In lanes 3–7, 250 g of total HeLa cell extracts were loaded. Lanes 4–7 contain full-length GFP-Mos1 transposase with no evidence of
protein degradation 20 h post transfection. The antibody against GFP recognizes an unspecific protein, which is present in all time points and the mock
control. Lane 7 shows lower signal for GFP-Mos1 protein since the cells have undergone division, which dilutes GFP-Mos1 concentration versus total
protein concentration.
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the best of our knowledge, chemical transfection of trans-
posases has not been reported to date. Genomic integration
has been observed previously after the integration products
of Tn5 (32) or Mu (46) transposition in vitro were intro-
duced into cells by electroporation. Electroporation of pro-
teins into cells is a well known procedure (47); however, we
are not aware of any published protocols which introduce
active transposons into cells via methods other than elec-
troporation or injection. The ability to function in cells fol-
lowing chemical transformation/transfection, at similar ef-
ficiencies to those seen with electroporation, may be unique
to mariner transposases, or it may be that other systems
such as EZ-Tn5™ are also effective following chemical trans-
formation procedures. Electroporation is difficult to auto-
mate; thus protocols, which do not require electroporation
offer the potential for automated high-throughput gener-
ation of insertion libraries. Mariner transposases can in-
tegrate transposons in any TA dinucleotide present in the
genome (36,48), providing an advantage for full genome
coverage.
As with other protein-based transposase systems, this
method allows screening of prokaryotic and eukaryotic host
organisms without the need for specific promoters, vectors
or delivery tools (49). This is a great advantage for biotech-
nology, which is seeking alternative chassis for production
of valuable compounds. Our method provides an IP-free
tool to deliver and integrate genes and pathways of inter-
est into prokaryotic and eukaryotic genomes. Therefore the
time for screening for the ideal organism, strain and posi-
tion of stable integration can be reduced dramatically. Nev-
ertheless, it should be noted that different organisms and
cell lines might require optimisation of protein concentra-
tion, transfection reagent and selection marker.
Moreover, as our method does not require DNA encod-
ing the transposase, it overcomes the problem of unstable
integration in the host cells, due to prolonged transposase
expression. The absence of the transposase gene precludes
its recombination with the host DNA, which could result in
constant expression of transposase leading to undesired ge-
nomic rearrangements. Since the transposase concentration
can be finely tuned by titration, overproduction inhibition
should not be a limitation for mariner transposition in vivo.
In summary,Mos1 andMboumar-9 offer a functional al-
ternative to other widely used commercial systems such as
EZ-Tn5™, with the added advantage that electroporation is
not required, opening the possibility for automated high-
throughput integration systems. The one-step method de-
scribed here is an open source tool, which has the potential
to be universally applied to facilitate research in basic mi-
crobiology, molecular biology and biotechnology, as well as
providing a one-step gene delivery and integration tool for
the generation of libraries, sequencing and gene therapy.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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